Open AccessSafety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV
Author(s) -
Jake A Ruddy,
Brian J. Boyarsky,
William A Werbel,
Justin R. Bailey,
Andrew H Karaba,
Jacqueline M Garonzik-Wang,
Dorry L. Segev,
Christine M. Durand
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002945
Subject(s) - antibody , virology , medicine , vaccination , immunology , antibody response , coronavirus , covid-19 , messenger rna , respiratory system , biology , gene , biochemistry , disease , infectious disease (medical specialty)
In this study of 12 people with HIV (PWH) who received the first dose of SARS-CoV-2 mRNA vaccination, anti-SARS-CoV-2 receptor-binding domain antibodies were detectable in all participants; lower antibody levels were seen in those with lower CD4+ counts, and vaccine reactions were generally mild.